- Home
- CYAB vs RDHL Comparison
CYAB vs RDHL Comparison
Compare CYAB & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CYAB | RDHL |
|---|---|---|
| Founded | 2017 | 2009 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4M | 5.4M |
| IPO Year | N/A | 2012 |
Fundamental Metrics
Financial Performance| Metric | CYAB | RDHL |
|---|---|---|
| Price | $0.36 | $0.73 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 157.7K | 80.2K |
| Earning Date | 04-09-2026 | 04-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $381.91 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.31 | $0.64 |
| 52 Week High | $2.99 | $3.31 |
Technical Indicators
Market Signals| Indicator | CYAB | RDHL |
|---|---|---|
| Relative Strength Index (RSI) | 33.67 | 39.61 |
| Support Level | N/A | N/A |
| Resistance Level | $0.50 | $0.91 |
| Average True Range (ATR) | 0.05 | 0.07 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 29.05 | 33.67 |
Price Performance
Historical ComparisonAbout CYAB Cyabra Inc. Common Stock
Cyabra Inc is an AI-powered SaaS company that detects and analyzes online disinformation. Its platform uses machine learning to monitor social media and news data in real time, identify fake accounts and harmful narratives, and assess content authenticity and sentiment.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.